Okyo Pharma appointed Robert J. Dempsey to serve as the company’s next CEO, according to a press release.
Dempsey has more than 20 years of experience in global ophthalmology and has held leadership roles at several companies. As group vice president and head of global ophthalmology at Shire, Dempsey led the launch of Xiidra (lifitegrast ophthalmic solution 5%, Bausch + Lomb) and its eventual sale to Novartis in 2019, according to the release.
Okyo said the move will support the company’s strategic direction as it advances urcosimod for the treatment of neuropathic corneal pain and ocular